Clinical and pathological characteristics of 385 late-POD patients, divided by second-line therapies
| . | All patients N = 385 . | BTKi n = 114 . | CIT n = 271 . | P value for comparison . |
|---|---|---|---|---|
| Median age (range) | 59 (19-70) | 57 (19-70) | 59 (35-70) | |
| <60 | 200 (52%) | 63 (55%) | 137 (50%) | .37 |
| Male sex | 292 (77%) | 86 (75%) | 206 (76%) | .94 |
| MIPI score | ||||
| Low | 144 (39%) | 43 (42%) | 101 (39%) | .71 |
| Intermediate | 131 (36%) | 40 (39%) | 91 (25%) | |
| High | 90 (25%) | 20 (19%) | 70 (26%) | |
| Morphology | ||||
| Blastoid or pleomorphic∗ | 40 (12%) | 12 (11%) | 28 (12%) | .68 |
| Ki-67, ≥30%∗ | 99 (44%) | 31 (38%) | 68 (47%) | .16 |
| TP53 mutational status∗ | 9 (15%) | 3 (17%) | 6 (14%) | .75 |
| Median time to POD | ||||
| Months (range) | 48 (24-165) | 48 (24-145) | 48 (24-165) | .49 |
| Up-front treatment | ||||
| RHyperCVAD/MTXHDAC | 53 (14%) | 15 (13%) | 66 (24%) | .06 |
| R-CHOP/DHAP + ASCT | 107 (28%) | 41 (36%) | 38 (14%) | |
| Nordic/R-HDS | 226 (58%) | 58 (51%) | 168 (62%) | |
| Country of enrollment | ||||
| Italy | 201 (52%) | 62 (54%) | 139 (51%) | .58 |
| Other countries | 184 (48%) | 52 (46%) | 132 (49%) |
| . | All patients N = 385 . | BTKi n = 114 . | CIT n = 271 . | P value for comparison . |
|---|---|---|---|---|
| Median age (range) | 59 (19-70) | 57 (19-70) | 59 (35-70) | |
| <60 | 200 (52%) | 63 (55%) | 137 (50%) | .37 |
| Male sex | 292 (77%) | 86 (75%) | 206 (76%) | .94 |
| MIPI score | ||||
| Low | 144 (39%) | 43 (42%) | 101 (39%) | .71 |
| Intermediate | 131 (36%) | 40 (39%) | 91 (25%) | |
| High | 90 (25%) | 20 (19%) | 70 (26%) | |
| Morphology | ||||
| Blastoid or pleomorphic∗ | 40 (12%) | 12 (11%) | 28 (12%) | .68 |
| Ki-67, ≥30%∗ | 99 (44%) | 31 (38%) | 68 (47%) | .16 |
| TP53 mutational status∗ | 9 (15%) | 3 (17%) | 6 (14%) | .75 |
| Median time to POD | ||||
| Months (range) | 48 (24-165) | 48 (24-145) | 48 (24-165) | .49 |
| Up-front treatment | ||||
| RHyperCVAD/MTXHDAC | 53 (14%) | 15 (13%) | 66 (24%) | .06 |
| R-CHOP/DHAP + ASCT | 107 (28%) | 41 (36%) | 38 (14%) | |
| Nordic/R-HDS | 226 (58%) | 58 (51%) | 168 (62%) | |
| Country of enrollment | ||||
| Italy | 201 (52%) | 62 (54%) | 139 (51%) | .58 |
| Other countries | 184 (48%) | 52 (46%) | 132 (49%) |
MIPI, Mantle Cell Lymphoma International Prognostic Index; Nordic/R-HDS, rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with rituximab and HD-AraC, followed by autologous stem cell transplantation; RHyperCVAD/MTXHDAC, fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone alternated with high-dose methotrexate and cytarabine; R-CHOP/DHAP + ASCT, R-CHOP alternated with cisplatin-cytarabine and dexamethasone, followed by autologous stem cell transplantation. Fifty-two patients received rituximab maintenance as consolidation of ASCT.
Data not available for all patients: MIPI available for 365; morphology for 335; Ki67 for 226; and TP53 mutation for 62. Differences between CIT and BTKi were similar when the analysis was limited to the 259 patients who were included and treated after 2014, when BTKi were available (P = .26 for age; P = .78 for sex; P = .58 for morphology; P = .29 for Ki67; and P = .33 for time to POD).